CIBC World Markets’s Nektar Therapeutics NKTR Stock Holding History

CIBC World Markets’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-2,641	Closed	-$26.9K	–	1798
2025 Q1	$26.9K	Buy	2,641 +1,527	+137%	+$20K	﹤0.01%	1773
2024 Q4	$15.5K	Buy	+1,114	New	+$19.6K	﹤0.01%	1309
2021 Q2	–	Sell	-1,304	Closed	-$391K	–	838
2021 Q1	$391K	Buy	+1,304	New	+$406K	﹤0.01%	893
2019 Q4	–	Sell	-4,202	Closed	-$1.15M	–	804
2019 Q3	$1.15M	Buy	4,202 +1,547	+58%	+$567K	0.01%	592
2019 Q2	$1.42M	Sell	2,655 -123	-4%	-$61.7K	0.01%	616
2019 Q1	$1.4M	Sell	2,778 -964	-26%	-$571K	0.01%	564
2018 Q4	$1.84M	Buy	3,742 +563	+18%	+$340K	0.02%	475
2018 Q3	$2.91M	Buy	3,179 +792	+33%	+$676K	0.02%	476
2018 Q2	$1.75M	Buy	2,387 +398	+20%	+$459K	0.02%	600
2018 Q1	$3.17M	Buy	+1,989	New	+$2.56M	0.03%	381

Other funds holding NKTR

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

CIBC World Markets's NKTR Position: Q2 2025 in Review

CIBC World Markets sold out of Nektar Therapeutics (NKTR) in Q2 2025, closing a stake of 2,641 shares — an estimated $26.9K sold.

CIBC World Markets first reported a position in NKTR in Q1 2018 and held it in 10 quarters. The position peaked at $3.17M in Q1 2018. 109 funds tracked by Wall St. Rank hold NKTR as of Q2 2025.

CIBC World Markets reported no remaining Nektar Therapeutics position as of Q2 2025 after selling out during the quarter.
CIBC World Markets sold 2,641 Nektar Therapeutics shares in Q2 2025, an estimated $26.9K.
CIBC World Markets first reported a position in Nektar Therapeutics in Q1 2018 and held it in 10 quarters.
CIBC World Markets's Nektar Therapeutics position peaked at $3.17M in Q1 2018.
109 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.